Examination of Hide Production, Hide Grades, and Economic Losses of Inferior Hide Grades in Egypt during 2002 to 2013

The study examined hide production and economic losses of inferior hide grades in Egypt during 2002 to 2013. Data were obtained from the Central Agency for Public Mobilization and Statistics for various livestock, and analyzed using descriptive statistics and one-way or two-way analysis of variance (ANOVA). The majority of hides produced were from buffaloes and were Grade 1 hides. Overall, the losses from condemned hides decreased from EGP1,756 in 2002 to EGP425 in 2013 (a decrease of 76%). Losses from Grade 3 hides also decreased from EGP141,369 in 2002 to EGP 63,859 in 2013 (a decrease of 55%). A concerted effort should be made to increase production from buffaloes to generate more revenues. Although the losses from both condemned and Grade 3 hides have been declining, we recommended the establishment of a buffalo hide quality grading system, and the development of an Extension education program to avoid activities that lead to losses

Assessment of the Impact of Bacillus Probiotics, Coconut Oil and Nigella sativa Oil on Productive Performance, Economic Indicators and Carcass Characteristics of cobb 500 Broiler Chickens

This experiment was conducted to evaluate the impact of dietary inclusion of probiotic mixture (B. subtilis and B. lieniformis), Coconut oil (CO) and Nigella sativa oil (NSO) or Black cumin oil (BCO) on productive performance, economic efficiency indicators and carcass characteristics of broiler chicks. For this purpose, 140 day-old broiler chicks (Cobb500) were weighed individually and assigned randomly into four treatments (T) 35 chicks in each, divided into five replicates of 7 chicks in each. (T1) control fed a basal diet, (T2) fed a basal diet + Coconut oil (10 ml/kg feed); (T3) fed a basal diet + Nigella sativa oil (1ml/kg feed) and (T4) fed a basal diet + bacillus probiotics (1g/kg of diet). Results clarified that CO, NSO and probiotic mixture groups improved significantly (P>0.05) the productive parameters (final body weight (FBW), body weight gain (BWG) and feed conversion ratio (FCR)) compared to control group. CO-based diet group recorded the highest BW and BWG, while probiotics mixture group was superior in feed intake value. The lowest FCR value was recorded in CO and NSO-based diet groups. The best economic efficiency measures were scored in CO followed by NSO then bacillus probiotics. Also, there are significant differences (P<0.05) among dietary treatments on relative weight of carcass, inner organs and immune organs. Diet containing NSO acquired the highest dressing percent (73.50%), while the highest relative weight of (heart, proventriculus, thymus, spleen %) was registered in broilers fed probiotics mixture diet. In conclusion CO, NSO, probiotics mixture-based diet has a beneficial influence on productive performance and economic indicators, thus highly recommended utilizing those supplements as natural feed additives

Comparative Appraisal of Relative Economic Efficiency of Spirulina, Cinnamon oil and Citric Acid Dietary Supplementations and Their Effect on Growth Performance and Carcass Traits in Broiler chicken

The aim of this research was to test the hypothesis of an improved growth, feed utilization efficiency, and economic efficiency (EE) of broiler chickens reared on different diets supplemented with spirulina (SPA), cinnamon oil (CO) and citric acid (CA). Total of 128 broiler chicken were divided randomly in to 4 group 32 chicks for each, with 4 replicants (8 bird/replicant).  Group1 (control) fed diet without any additives. Group2 fed control diet + spirulina (2g /kg feed). Group3 fed control diet + cinnamon oil (1ml /kg feed). Group4 fed control diet + citric acid (5g /kg feed). The result indicated that SPA, CO, and CA has a significant effect at (p<0.05) on growth performance parameters (feed intake (FI), weight gain (WG) and feed conversion ratio (FCR)). SPA recorded the highest FI while CA recorded the lowest value. It was noticed that SPA and CA do better than CO in live weight and weight gain. The best FCR was in CA group (1.61). SPA and CA has considerable effect at (P<0.05) on dressing percent while, CO had no significant effect. CO and CA had a significant impact at (P<0.05) on thymus relative weight. From The Economic point of view CA and SPA in the select doses had improved economic measures and relative economic efficiency (REE) indicating high return and net profit, benefit cost ratio, profitability percent, net profit margin. In contrast CO had no distinct effect on these parameters in the selected dose. Bearing in mind that citric acid had a preference in improving economic efficiency over spirulina. SPA, CO and CA may be used as feed additives for broiler chicken to enhance growth performance, Economically CA and SPA in the selected doses is better to increase return and profitability. Citric acid has the advantage in terms of its presence in the market and its low price compared to spirulina

Productive and Economic Efficiency of Some Layer Farms in Egypt

Egg production is an important factor that helps to meet the nutritional needs of the growing populations in developing countries. Commercial egg production is a source of high quality protein and income compared to other livestock production activities. The study used a multiple regression profit model to estimate the effect of breeds and housing system on profitability. Data were collected from 100 randomly selected layer farms in (Al Sharkia and Ismailia) during the period from 2019 to 2022, through research questionnaires. Results showed that hen reared in closed system had higher egg production, higher total return than those reared in the opened system. Lohman breed are more tolerable to the Egyptian conditions in the study area as shown by lower mortality % and lower values of total veterinary management (TVM). Layer farms in the study area were operating in the second stage of production. Therefore, layer farms are considered a good investment for both private and government sectors

Economic Comparison for the Effect of Breeds and Housing Systems on Broiler Farms Production and Profit

Broiler production is a promising sector to achieve food security and economic development in Egypt. It has a big share in animal protein supply which can relieve the problem of animal protein shortage. This study focused on estimating broiler farms profitability after the major financial changes that took place in Egypt, by studying how different housing systems and broiler breeds can affect farm production and profitability. Farm records and research questionnaires were used to collect data from broiler farms in two governorates (Al Sharkia and Ismailia). Different broiler breeds and housing systems were compared. Results showed that despite the high cost of production, broiler production is still a profitable business appealing for further private or governmental investments. The veterinary management, housing system and breed have a positive effect on the productivity. The highest production was obtained for Cobb breed and closed systems, whereas Ross breed achieved the highest net profit. Despite the challenges faced by producers, it was concluded that broiler farms in the study area are acting in the second stage of production where resources are probably used for the existing conditions

Productive and Economic Efficiency of Some Layer Farms in Egypt

Egg production is an important factor that helps to meet the nutritional needs of the growing populations in developing countries. Commercial egg production is a source of high quality protein and income compared to other livestock production activities. The study used a multiple regression profit model to estimate the effect of breeds and housing system on profitability. Data were collected from 100 randomly selected layer farms in (Al Sharkia and Ismailia) during the period from 2019 to 2022, through research questionnaires. Results showed that hen reared in closed system had higher egg production, higher total return than those reared in the opened system. Lohman breed are more tolerable to the Egyptian conditions in the study area as shown by lower mortality % and lower values of total veterinary management (TVM). Layer farms in the study area were operating in the second stage of production. Therefore, layer farms are considered a good investment for both private and government sectors

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background: The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods: Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings: Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation: Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding: Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Data were assessed overall and by WHO regions, sex, and index versus non-index cases. Findings Of the 61 612 individuals in the registry, 42 167 adults (21 999 [53·6%] women) from 56 countries were included in the study. Of these, 31 798 (75·4%) were diagnosed with the Dutch Lipid Clinic Network criteria, and 35 490 (84·2%) were from the WHO region of Europe. Median age of participants at entry in the registry was 46·2 years (IQR 34·3–58·0); median age at diagnosis of familial hypercholesterolaemia was 44·4 years (32·5–56·5), with 40·2% of participants younger than 40 years when diagnosed. Prevalence of cardiovascular risk factors increased progressively with age and varied by WHO region. Prevalence of coronary disease was 17·4% (2·1% for stroke and 5·2% for peripheral artery disease), increasing with concentrations of untreated LDL cholesterol, and was about two times lower in women than in men. Among patients receiving lipid-lowering medications, 16 803 (81·1%) were receiving statins and 3691 (21·2%) were on combination therapy, with greater use of more potent lipid-lowering medication in men than in women. Median LDL cholesterol was 5·43 mmol/L (IQR 4·32–6·72) among patients not taking lipid-lowering medications and 4·23 mmol/L (3·20–5·66) among those taking them. Among patients taking lipid-lowering medications, 2·7% had LDL cholesterol lower than 1·8 mmol/L; the use of combination therapy, particularly with three drugs and with proprotein convertase subtilisin–kexin type 9 inhibitors, was associated with a higher proportion and greater odds of having LDL cholesterol lower than 1·8 mmol/L. Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0·001). Interpretation Familial hypercholesterolaemia is diagnosed late. Guideline-recommended LDL cholesterol concentrations are infrequently achieved with single-drug therapy. Cardiovascular risk factors and presence of coronary disease were lower among non-index cases, who were diagnosed earlier. Earlier detection and greater use of combination therapies are required to reduce the global burden of familial hypercholesterolaemia. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron